v3.26.3
Asset Purchases and Sales (Details Narrative) - USD ($)
1 Months Ended
Apr. 30, 2026
Oct. 30, 2024
Jun. 30, 2026
Dec. 31, 2025
Asset Acquisition [Line Items]        
Convertible note     $ 2,862,000 $ 2,687,000
Milestone payments $ 500,000      
Nex Gel License Agreement [Member]        
Asset Acquisition [Line Items]        
Net proceeds 4,800,000      
Deferred payment     600,000  
Milestone payments 20,000,000.0      
First milestone payments 2,500,000      
Revenues 25,000,000.0      
Nex Gel License Agreement [Member] | Minimum [Member]        
Asset Acquisition [Line Items]        
Revenues 15,000,000.0      
Nex Gel License Agreement [Member] | Sequence Life Sciences Inc [Member]        
Asset Acquisition [Line Items]        
Pay sales commissions 2,500,000      
Sequence LifeScience Inc [Member]        
Asset Acquisition [Line Items]        
Asset acquisition price of acquisition expected   $ 5,500,000    
Cash payment   1,500,000    
Monthly milestone payments   $ 4,000,000    
Net sales percentage   20.00%    
Accured milestone payments     $ 0 $ 3,127,000
Nex Gel Inc. [Member] | Nex Gel License Agreement [Member]        
Asset Acquisition [Line Items]        
Asset acquisition price of acquisition expected 13,300,000      
Pay sales commissions 2,900,000      
Convertible note $ 5,000,000.0